Algeria
Tuberculosis profile
Population  2013 39 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 5.1 (2.2–8.4) 13 (5.6–21)
Mortality (HIV+TB only) 0.035 (0–0.3) 0.09 (0–0.77)
Prevalence  (includes HIV+TB) 49 (25–82) 126 (64–209)
Incidence  (includes HIV+TB) 32 (26–38) 81 (67–98)
Incidence (HIV+TB only) 0.12 (0.11–1) 0.3 (0.29–2.6)
Case detection, all forms (%) 66 (54–79)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.4 (0.6–2.7) 9.1 (1.1–29)
MDR-TB cases among notified pulmonary
TB cases
120 (51–230) 45 (6–150)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 7 489   358
Pulmonary, clinically diagnosed 1 094   0
Extrapulmonary 11 760   0
       
Total new and relapse 20 701    
Previously treated, excluding relapses 140    
Total cases notified 20 841    
Among 7 124 new cases:
75 (1%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB      
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment      
TB/HIV 2013 Number (%)
TB patients with known HIV status    
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 90
Previously treated cases, excluding relapse, registered in 2012 74
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.6
Culture (per 5 million population)  
Drug susceptibility testing (per 5 million population)  
Sites performing Xpert MTB/RIF  
Is second-line drug susceptibility testing available?  
Financing TB control 2014  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-19 Data: www.who.int/tb/data